Xeris details XP-8121 Phase 3 plan; expects $1-3B peak revenue, launch in 2030

Xeris Biopharma Holdings, Inc.

Phase 3 Cornerstone study: 500 patients, 1:1 vs oral levothyroxine, 54 weeks, primary endpoint TSH normal at weeks 48/54.
Topline results expected late 2028; FDA approval and launch anticipated 2030.
Peak net revenue potential $1-3 billion for once-weekly subcutaneous levothyroxine.
Additional studies: pediatric (Capstone), special population (Touchstone), real-world evidence.
KOL Dr. David Robertson to serve as Cornerstone investigator.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.